Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial

AETHLON MEDICAL INC

2025-Q1 EPS reported -$0.34 vs consensus -$10.30 ▲ beat (+96.7%)

Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.
Cash balance $9.1M as of June 30, 2024.
Ethics approvals granted for Hemopurifier safety study in solid tumor patients on anti-PD-1 therapy.
Expects to open patient enrollment in October 2024; additional sites anticipated by end of 2024.
COVID-19 trial in India remains open; one patient treated to date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.